速递｜替尔泊肽在治疗肥胖男性性腺功能减退方面优于传统睾酮补充疗法

Core Viewpoint - Tirzepatide may provide a superior treatment option for men with obesity-related functional hypogonadism, showing significant weight loss and improved testosterone levels compared to testosterone replacement therapy (TRT) or no treatment [1][2]. Group 1: Study Findings - The study involved 83 men with obesity, functional hypogonadism, and insulin resistance, where those treated with tirzepatide for two months experienced an average weight loss of 8.1% [4]. - Participants were divided into three groups: 28 received tirzepatide, 30 received no medication, and 25 received TRT, with all advised to follow a low-calorie diet and engage in daily walking [4]. - Improvements in erectile function, measured by the International Index of Erectile Function (IIEF-5), were more significant in the tirzepatide group compared to the lifestyle intervention group [4][5]. Group 2: Hormonal Changes - The tirzepatide group showed significantly higher levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and total testosterone, while estradiol (E2) levels were lower compared to the other groups [5]. - The study suggests that tirzepatide not only aids in weight loss but also rapidly restores hormonal balance, indicating a potential regulatory effect on the hypothalamic-pituitary-gonadal axis [5]. Group 3: Clinical Implications - Experts suggest that tirzepatide could be prioritized over direct testosterone therapy for patients willing to try GLP-1 medications, as it addresses underlying metabolic issues rather than merely substituting testosterone [2][5]. - The findings align with previous research indicating that weight loss can improve fertility, testosterone levels, and sexual function in men [2].